The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

That’s more than $1.2 billion in unpaid royalties BioNTech is expected to pay for the Pfizer-BioNTech COVID-19 vaccine sales.

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

According to earlier statements by BioNTech, the dispute with the university was about "non-exclusive rights" to patent applications used in the Covid-19 vaccine from BioNTech and Pfizer.

The world first became aware of Covid-19 five years ago. We evaluate where we are, remember how we got here, and consider ...

The BioNTech/Pfizer jab was the first COVID-19 vaccine to be authorized by a stringent regulatory authority for emergency use and the first to be approved for regular use.

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.